Silver Book Fact

In 2010, ~67,500 SAVRs were performed in the U.S.

Fact image

Clark M, Duhay F, Thompson A, Keyes M, et al. Clinical and Economic Outcomes After Surgical Aortic Valve Replacement in Medicare Patients. Risk Manag Healthc Policy. 2012; 2012(5). https://www.dovepress.com/clinical-and-economic-outcomes-after-surgical-aortic-valve-replacement-peer-reviewed-article-RMHP

Reference

Title
Clinical and Economic Outcomes After Surgical Aortic Valve Replacement in Medicare Patients
Publication
Risk Manag Healthc Policy
Publication Date
2012
Authors
Clark M, Duhay F, Thompson A, Keyes M, et al.
Volume & Issue
Volume 2012, Issue 5
Pages
117-26
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
  • Undertreatment of patients with sSAS
    AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on.  
  • Life expectancy and quality of life gains from AVR
    A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years…  
  • Survival Rates of SAS Patients with and without SAVR
    Patients with severe aortic stenosis (SAS) ages 80+ who underwent surgical aortic valve replacement (SAVR) have 1-year, 2-year, and 5-year survival rates of 87%, 78%, and 68% respectively — compared with…  
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…